Company profile
BIOHAVEN LTD.
NYSE:BHVNBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OPAKALIM | phase2_3 | — | 9 | active |
| RILUZOLE | phase1 | — | 3 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06874335 | phase1 | recruiting | 2025-03-20 | 2029-03-01 | Biohaven Therapeutics Ltd. | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors |
| NCT06384807 | phase1_2 | recruiting | 2024-04-22 | 2028-02-01 | Biohaven Therapeutics Ltd. | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors |
| NCT07262268 | phase1 | enrolling_by_invitation | 2026-01-15 | 2026-11-01 | Biohaven Therapeutics Ltd. | A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia |
| NCT07642050 | phase3 | not_yet_recruiting | 2026-06-01 | 2028-09-01 | Biohaven Therapeutics Ltd. | A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy |
| NCT06425159 | phase2_3 | terminated | 2024-06-20 | 2026-03-12 | Biohaven Therapeutics Ltd. | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures |
FDA applications (0)
No records yet.